FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice.
The effects of FK506, a new immunosuppressive agent, on the development of lupus dermatoses were investigated in the autoimmune-prone MRL/Mp-lpr/lpr (MRL/lpr) mouse, which is an animal model for the spontaneous development of skin lesions similar to those of human lupus erythematosus (LE). FK506 reduced the incidence of skin lesions, lupus nephritis, the titre of serum anti-double-stranded DNA antibodies and the massive T cell proliferation. The incidence and magnitude of IgG deposition at the dermoepidermal junction were not changed. These results suggest that FK506 is a promising immunosuppressive agent for the control of autoimmune skin diseases.
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D004195:Disease Models, Animal; D005260:Female; D007074:Immunoglobulin G / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D051379:Mice; D011507:Proteinuria / Q000517:prevention & control; D013163:Splenomegaly / Q000517:prevention & control; D016559:Tacrolimus / Q000008:administration & dosage / Q000627:therapeutic use*
D000974:Antibodies, Antinuclear; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016559:Tacrolimus